search
Back to results

RaGuS Trial by Postoperative Patients (RaGuS)

Primary Purpose

Vasoplegic Syndrome, Sirs Due to Noninfectious Process Without Organ Dysfunction, Orthostatic Hypotension

Status
Unknown status
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Midodrine Hydrochloride
Placebo
Sponsored by
Bürgerspital Solothurn
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Vasoplegic Syndrome focused on measuring Midodrine, Vasoplegic syndrome, Noradrenaline, SIRS

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Over 18 years of age
  • Need of vasoactive drugs after three hours from arrival and adequate volume recovery.

Exclusion Criteria:

  • Signs of infection (anamnesis or pro-calcitonin > 0.2 with leukocytosis, CRP and/or fever)
  • Serum lactate > 2mmol/l
  • Mechanical ventilation
  • Therapeutic restrictions or comfort measures at arrival
  • "de novo" or acute on chronic heart failure (Reduction of known ejection fraction for more than 20 percent, signs of acute lung edema)
  • Pregnant
  • Patients with digoxin treatment or history of glaucoma.
  • History of midodrine allergy, pheochromocytoma, thyrotoxicosis, tachyarrhythmias or ventricular fibrillation.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Placebo Comparator

    Arm Label

    Intervention group

    Control group

    Arm Description

    Midodrine will be administered every 8 hours, increasing the dose gradually until a maximum of 30 mg a day is reached. It will be given orally in the following sequence: 2.5 mg - 5 mg - 7.5 mg - 10 mg. The target standard perfusion pressure for all the patients will be a mean arterial pressure (MAP) > 65 mmHg, with unchanged dose of midodrine after target pressure is reached. If the pressure continues to increase, the same sequence will be followed for dose de-escalation.

    By placebo group will be followed the same strategy.The target standard perfusion pressure for all the patients will be a mean arterial pressure (MAP) > 65 mmHg, with unchanged dose of placebo after target pressure is reached. If the pressure continues to increase, the same sequence will be followed for dose de-escalation.

    Outcomes

    Primary Outcome Measures

    Time
    Hours from initiation of treatment with midodrine to discharge from critical care area

    Secondary Outcome Measures

    Length of stay
    days in critical care area and hospital
    Vasopresors
    Noradrenalin needed doses
    Fluid balance
    cumulative fluid balance in mililiter

    Full Information

    First Posted
    June 13, 2020
    Last Updated
    June 18, 2020
    Sponsor
    Bürgerspital Solothurn
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04440085
    Brief Title
    RaGuS Trial by Postoperative Patients
    Acronym
    RaGuS
    Official Title
    RANDOMIZED CASE-CONTROLLED TRIAL ASSESSING MIDODRINE (GUTRON®) IN POSTOPERATIVE VASOPLEGIC PATIENTS
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2020
    Overall Recruitment Status
    Unknown status
    Study Start Date
    September 14, 2020 (Anticipated)
    Primary Completion Date
    September 30, 2020 (Anticipated)
    Study Completion Date
    September 14, 2021 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Bürgerspital Solothurn

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Vasoplegic syndrome is characterized clinically by reduced systemic vascular resistance and normal or increased cardiac output. It is principally observed in cardiovascular and orthopedic interventions and is characterized by a systemic inflammatory response with the inability of the vascular endothelial muscles to contract and a resistance to the action of vasoactive drugs. This event extends the length of stay in the critical care area due to the need of vasoactive drugs. The investigators aim to assess the standardized application of midodrine in postoperative patients without sepsis and need of vasoactive drugs in order to reduce the length of stay in critical care area and for extension in hospital.
    Detailed Description
    Midodrine is an alpha 1 receptor agonist used usually in cases of hypotension helping to increase blood pressure. The main indication is orthostatic hypotension but there are other clinical conditions where this medicament is often used like hypotension by dialysis, hepatorenal syndrome and after carotid artery stenting. Vasoplegic syndrome coul be interpreted as a variant of orthostatic hypotension that happens usually after surgical interventions. It produces a loss of systemic vascular resistance due to inflammatory reaction without any signs of infection. The investigators aim to conduct a randomized, double-blind, single-center, placebo-controlled study of midodrine in patients who present postoperative vasoplegia with no active signs of sepsis but need of vasoactive drugs (Noradrenalin).

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Vasoplegic Syndrome, Sirs Due to Noninfectious Process Without Organ Dysfunction, Orthostatic Hypotension
    Keywords
    Midodrine, Vasoplegic syndrome, Noradrenaline, SIRS

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Sequential Assignment
    Model Description
    Randomized, double-blind, single-center, placebo-controlled study
    Masking
    ParticipantCare ProviderInvestigator
    Allocation
    Randomized
    Enrollment
    50 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Intervention group
    Arm Type
    Active Comparator
    Arm Description
    Midodrine will be administered every 8 hours, increasing the dose gradually until a maximum of 30 mg a day is reached. It will be given orally in the following sequence: 2.5 mg - 5 mg - 7.5 mg - 10 mg. The target standard perfusion pressure for all the patients will be a mean arterial pressure (MAP) > 65 mmHg, with unchanged dose of midodrine after target pressure is reached. If the pressure continues to increase, the same sequence will be followed for dose de-escalation.
    Arm Title
    Control group
    Arm Type
    Placebo Comparator
    Arm Description
    By placebo group will be followed the same strategy.The target standard perfusion pressure for all the patients will be a mean arterial pressure (MAP) > 65 mmHg, with unchanged dose of placebo after target pressure is reached. If the pressure continues to increase, the same sequence will be followed for dose de-escalation.
    Intervention Type
    Drug
    Intervention Name(s)
    Midodrine Hydrochloride
    Intervention Description
    All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Midodrine will be administered according to the evolution of the patient's mean pressure.
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Intervention Description
    All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Placebo will be administered according to the evolution of the patient's mean pressure.
    Primary Outcome Measure Information:
    Title
    Time
    Description
    Hours from initiation of treatment with midodrine to discharge from critical care area
    Time Frame
    aproximately 2 days
    Secondary Outcome Measure Information:
    Title
    Length of stay
    Description
    days in critical care area and hospital
    Time Frame
    aproximately 7 days
    Title
    Vasopresors
    Description
    Noradrenalin needed doses
    Time Frame
    aproximately 2 days
    Title
    Fluid balance
    Description
    cumulative fluid balance in mililiter
    Time Frame
    aproximately 2 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    99 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Over 18 years of age Need of vasoactive drugs after three hours from arrival and adequate volume recovery. Exclusion Criteria: Signs of infection (anamnesis or pro-calcitonin > 0.2 with leukocytosis, CRP and/or fever) Serum lactate > 2mmol/l Mechanical ventilation Therapeutic restrictions or comfort measures at arrival "de novo" or acute on chronic heart failure (Reduction of known ejection fraction for more than 20 percent, signs of acute lung edema) Pregnant Patients with digoxin treatment or history of glaucoma. History of midodrine allergy, pheochromocytoma, thyrotoxicosis, tachyarrhythmias or ventricular fibrillation.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Marcos Delgado, MD
    Phone
    +4132627
    Ext
    3820
    Email
    marcos.delgado@spital.so.ch
    First Name & Middle Initial & Last Name or Official Title & Degree
    René Fahrner, MD
    Phone
    +4132627
    Ext
    3398
    Email
    r.fahrner@web.de
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Marcos Delgado, MD
    Organizational Affiliation
    Bürgerspital Solothurn
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    IPD Sharing Plan Description
    We have decided for the Trial not to share the participant Information.
    Citations:
    PubMed Identifier
    32145658
    Citation
    Tchen S, Sullivan JB. Clinical utility of midodrine and methylene blue as catecholamine-sparing agents in intensive care unit patients with shock. J Crit Care. 2020 Jun;57:148-156. doi: 10.1016/j.jcrc.2020.02.011. Epub 2020 Feb 19.
    Results Reference
    result
    PubMed Identifier
    29223724
    Citation
    Shaefi S, Mittel A, Klick J, Evans A, Ivascu NS, Gutsche J, Augoustides JGT. Vasoplegia After Cardiovascular Procedures-Pathophysiology and Targeted Therapy. J Cardiothorac Vasc Anesth. 2018 Apr;32(2):1013-1022. doi: 10.1053/j.jvca.2017.10.032. Epub 2017 Oct 27.
    Results Reference
    result
    PubMed Identifier
    26492477
    Citation
    Jans O, Mehlsen J, Kjaersgaard-Andersen P, Husted H, Solgaard S, Josiassen J, Lunn TH, Kehlet H. Oral Midodrine Hydrochloride for Prevention of Orthostatic Hypotension during Early Mobilization after Hip Arthroplasty: A Randomized, Double-blind, Placebo-controlled Trial. Anesthesiology. 2015 Dec;123(6):1292-300. doi: 10.1097/ALN.0000000000000890.
    Results Reference
    result
    PubMed Identifier
    31334462
    Citation
    Smits M, Lin S, Rahme J, Bailey M, Bellomo R, Hardidge A. Blood Pressure and Early Mobilization After Total Hip and Knee Replacements: A Pilot Study on the Impact of Midodrine Hydrochloride. JB JS Open Access. 2019 May 14;4(2):e0048. doi: 10.2106/JBJS.OA.18.00048. eCollection 2019 Apr-Jun.
    Results Reference
    result
    PubMed Identifier
    23845791
    Citation
    Levine AR, Meyer MJ, Bittner EA, Berg S, Kalman R, Stanislaus AB, Ryan C, Ball SA, Eikermann M. Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions. J Crit Care. 2013 Oct;28(5):756-62. doi: 10.1016/j.jcrc.2013.05.021. Epub 2013 Jul 8.
    Results Reference
    result
    Citation
    Cardenas-Garcia JL, Whitson MR, Healy K, Koenig S, Narasimhan M, Mayo P: Safety of oral midrodrine as a mehtod of weaning from intravenous vasoactive medication in the medical intensive care unit. Chest 2014, 146(4):224A.
    Results Reference
    result
    PubMed Identifier
    31107279
    Citation
    Rizvi MS, Nei AM, Gajic O, Mara KC, Barreto EF. Continuation of Newly Initiated Midodrine Therapy After Intensive Care and Hospital Discharge: A Single-Center Retrospective Study. Crit Care Med. 2019 Aug;47(8):e648-e653. doi: 10.1097/CCM.0000000000003814.
    Results Reference
    result
    PubMed Identifier
    26953217
    Citation
    Whitson MR, Mo E, Nabi T, Healy L, Koenig S, Narasimhan M, Mayo PH. Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock. Chest. 2016 Jun;149(6):1380-3. doi: 10.1016/j.chest.2016.02.657. Epub 2016 Mar 4.
    Results Reference
    result
    PubMed Identifier
    28327122
    Citation
    Anstey MH, Wibrow B, Thevathasan T, Roberts B, Chhangani K, Ng PY, Levine A, DiBiasio A, Sarge T, Eikermann M. Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial). BMC Anesthesiol. 2017 Mar 21;17(1):47. doi: 10.1186/s12871-017-0339-x.
    Results Reference
    result

    Learn more about this trial

    RaGuS Trial by Postoperative Patients

    We'll reach out to this number within 24 hrs